Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype

10 January 2024 - Approval based on a separate Phase 3 trial among Chinese patients reinforcing mepolizumab’s efficacy and safety ...

Read more →

Leqembi approved for the treatment of Alzheimer's disease in China

9 January 2024 - BioArctic's partner Eisai announced today that Leqembi (lecanemab-irmb) has been approved in China as a treatment for ...

Read more →

Beyfortus approved in China for the prevention of RSV disease in infants

2 January 2024 - First and only RSV preventive option authorised for use in China ...

Read more →

Takeda announces China NMPA approval of Livtencity (maribavir) for the treatment of adults with post-transplant cytomegalovirus refractory to prior therapies

21 December 2023 - Approval based on Phase 3 TAK-620-303 SOLSTICE study demonstrating maribavir was superior to conventional therapies at week ...

Read more →

RemeGen announces continued inclusion of telitacicept and disitamab vedotin in China National Reimbursement Drug List, ensuring continuous accessibility of innovative drugs for more patients

18 December 2023 - RemeGen has recently confirmed that under the 2023 simple renewal mechanism of China National Healthcare Security ...

Read more →

AnHeart Therapeutics and Innovent Announce China’s NMPA has granted taletrectinib (ROS1 inhibitor) priority review designation

18 December 2023 -AnHeart Therapeutics and Innovent Biologics today announced the Center for Drug Evaluation of China’s National Medical Products ...

Read more →

Zai Lab announces the first listing of Vyvgart (efgartigimod alfa) and other updates in China’s National Reimbursement Drug List

12 December 2023 - Zai Lab today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare ...

Read more →

Antengene announces inclusion of Xpovio (selinexor) in 2023 China's National Reimbursement Drug List

13 December 2023 - Antengene today announced that Xpovio (selinexor) has been added to the National Reimbursement Drug List (2023 Version) ...

Read more →

Hutchmed announces continued inclusion of Elunate (fruquintinib) and Sulanda (surufatinib) in the National Reimbursement Drug List in China at current terms

12 December 2023 - Hutchmed today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration, ...

Read more →

CStone announces NMPA approval of sugemalimab as first-line treatment for oesophageal squamous cell carcinoma

8 December 2023 - This marks the 13th new drug application approval obtained by CStone and sugemalimab's fourth indication approved in ...

Read more →

Apollomics announces the first approval of vebreltinib for MET exon 14 skip non-small-cell lung cancer

16 November 2023 - Compelling clinical data serving as basis of this approval supports continued development of vebreltinib for the rest ...

Read more →

Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer

14 November 2023 - Approval based on results from TOPAZ-1 global Phase 3 trial and a Chinese patient cohort which ...

Read more →

CASI Pharmaceuticals announces market approval of CNCT19 by China NMPA

8 November 2023 - CASI Pharmaceuticals is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy.  ...

Read more →

CStone announces NMPA approval of sugemalimab for patients with relapsed or refractory extranodal NK/T-cell lymphoma, the first anti-PD-1/PD-L1 mAb approved for this indication

31 October 2023 - Sugemalimab is the world’s first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refractory extranodal NK/T-cell lymphoma indication. ...

Read more →

ViiV Healthcare receives approval from China’s National Medical Products Administration for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment

26 October 2023 - The marketing authorisation for rilpivirine long-acting injection was received on the 18 October 2023. ...

Read more →